Immunic Stock Gets Reduced EPS Estimate from HC Wainwright

Immunic logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright cut its FY2030 EPS estimate for Immunic to $0.33 from $0.40, while maintaining a Buy rating and a $22 price target.
  • Analyst views are mixed, but the overall consensus is Moderate Buy, with an average price target of $35.43.
  • Immunic reported a quarterly loss of $0.99 per share, missing the consensus estimate of a $0.79 loss by $0.20.
  • MarketBeat previews the top five stocks to own by December 1st.

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at HC Wainwright dropped their FY2030 EPS estimates for shares of Immunic in a note issued to investors on Monday, November 16th. HC Wainwright analyst M. Caufield now expects that the company will post earnings of $0.33 per share for the year, down from their previous estimate of $0.40. HC Wainwright currently has a "Buy" rating and a $22.00 price target on the stock. The consensus estimate for Immunic's current full-year earnings is ($3.69) per share.

Other equities research analysts also recently issued reports about the company. Weiss Ratings restated a "sell (d-)" rating on shares of Immunic in a report on Wednesday, August 26th. Cantor Fitzgerald started coverage on shares of Immunic in a report on Friday, October 23rd. They issued an "overweight" rating for the company. Wall Street Zen lowered shares of Immunic from a "sell" rating to a "strong sell" rating in a research note on Saturday. Ladenburg Thalmann & Co. Inc. raised shares of Immunic to a "strong-buy" rating in a report on Wednesday, July 29th. Finally, Zacks Research downgraded shares of Immunic from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, November 10th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $35.43.

Get Our Latest Research Report on Immunic

Immunic Stock Performance

Shares of IMUX stock opened at $7.23 on Tuesday. The firm has a fifty day simple moving average of $8.58 and a 200-day simple moving average of $11.53. Immunic has a twelve month low of $5.06 and a twelve month high of $17.43.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its earnings results on Friday, November 13th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.20).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of IMUX. Braidwell LP acquired a new position in shares of Immunic during the second quarter worth approximately $9,914,000. Bank of America Corp DE raised its stake in shares of Immunic by 80,724.2% in the 1st quarter. Bank of America Corp DE now owns 143,867 shares of the company's stock worth $160,000 after buying an additional 143,689 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new position in shares of Immunic during the 1st quarter valued at about $187,000. Renaissance Technologies LLC bought a new stake in Immunic during the first quarter worth approximately $1,020,000. Finally, Avidity Partners Management LP grew its holdings in shares of Immunic by 42.6% in the 1st quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company's stock worth $7,436,000 after acquiring an additional 2,000,000 shares during the last quarter. Institutional investors own 51.82% of the company's stock.

Immunic Company Profile

(Get Free Report)

Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company's research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.

Further Reading

Earnings History and Estimates for Immunic (NASDAQ:IMUX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Immunic Right Now?

Before you consider Immunic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.

While Immunic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines